Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
77 hedge funds and large institutions have $379M invested in Repros Therapeutics Inc. in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 12 closing their positions.
0% more capital invested
Capital invested by funds: $379M → $379M (+$376K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 80 → 77 (-3)
14% less call options, than puts
Call options by funds: $9.62M | Put options by funds: $11.2M
24% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 29
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$7.22M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$6.36M |
| 3 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$5.38M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$4.24M |
| 5 |
DCM
Destrier Capital Management
New York
|
+$3.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.58M |
| 3 |
QF
QVT Financial
New York
|
-$2.96M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.7M |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$2.5M |
RPRX Hedge Fund Activity: Q2 2014 in Review
77 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q2 2014, worth a combined $379M — up 0.1% from $379M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RPRX and 9 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 22 added.
The largest buyer was Sarissa Capital Management, adding an estimated $7.22M. The largest seller was PFM Health Sciences, cutting an estimated $4.3M.
- 77 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q2 2014, down from 80 in Q1 2014.
- Funds reported $379M of Repros Therapeutics Inc. stock for Q2 2014, up 0.1% quarter-over-quarter.
- 9 funds opened new Repros Therapeutics Inc. positions in Q2 2014 and 12 closed out, a net change of -3 holders.
- The largest Repros Therapeutics Inc. buyer in Q2 2014 was Sarissa Capital Management, an estimated $7.22M added.
- The largest Repros Therapeutics Inc. seller in Q2 2014 was PFM Health Sciences, an estimated $4.3M sold.
Based on aggregated 13F filings for Q2 2014.